Antibody Binding Site Engineering for Methotrexate Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for measuring methotrexate (MTX) in biological samples face challenges such as high cross-reactivity with metabolites like DAMPA and 7-hydroxymethotrexate, leading to inaccurate quantification and toxicity monitoring issues during high-dose MTX therapy.
Innovation Solution
Development of antibodies with specific binding affinity to methotrexate, characterized by unique nucleotide and amino acid sequences, which are used in competitive assays to detect MTX with low cross-reactivity, enabling sensitive and accurate quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If commercial MTX immunoassays are used for detection, then the assay can be performed with standard procedures, but the cross-reactivity with DAMPA is high leading to inaccurate quantification
Solution Approach 1:
The patent modifies the antibody binding site to have differential affinity characteristics - high affinity for MTX and low affinity for DAMPA. This local differentiation in binding properties allows the antibody to selectively recognize MTX while rejecting structurally similar metabolites, resolving the contradiction between measurement precision and reliability
Solution Approach 2:
The patent changes the binding parameters of the antibody by selecting or engineering antibodies with specific kinetic properties (KD values) that favor MTX binding over DAMPA binding. By adjusting the binding affinity parameters through antibody selection or modification, the assay achieves both high precision for MTX quantification and high reliability by minimizing cross-reactivity
2Measurement precision
If HPLC-MS is used for MTX detection, then accurate detection can be achieved, but the procedure requires considerable lab setup, extensive sample preparation and long turn-around time
Solution Approach 1:
The patent extracts the critical detection function from the complex HPLC-MS system and implements it through a simplified immunoassay format. By using antibodies that provide sufficient specificity and sensitivity, the patent removes the need for extensive sample preparation and complex instrumentation while maintaining accurate MTX detection, thus reducing turn-around time without sacrificing measurement precision
Solution Approach 2:
The patent creates a simplified version of the HPLC-MS detection capability using immunoassay technology. The antibody-based detection system replicates the specificity and sensitivity of mass spectrometry for MTX detection but in a format that requires minimal sample preparation and can be performed in routine clinical laboratories, thereby achieving accurate detection with reduced time loss
3Ease of operation
If existing immunoassays are used, then the assay procedure is simplified, but the cross-reactivity with metabolites leads to reduced measurement precision
Solution Approach 1:
The patent enhances the local binding properties of the antibody to achieve high specificity for MTX while maintaining the simplicity of the immunoassay format. The modified antibody exhibits differential binding characteristics that provide measurement precision comparable to or better than HPLC-MS, while the assay procedure remains simple and suitable for routine clinical use
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide a highly sensitive and specific method for detecting MTX, reducing cross-reactivity with metabolites and improving the accuracy of MTX quantification, thereby optimizing dosing and toxicity monitoring in high-dose MTX therapy.
Implementation Method 1
antibodies having binding specificity to methotrexate
Implementation Method 2
combining in a solution the sample with a capture molecule and a labeled MTX, wherein the capture molecule is capable of binding the labeled MTX, and wherein MTX when present in the sample competes with the labeled MTX for binding to the capture molecule
Data Source
AI summary
The disclosure relates generally to methods of detecting and quantifying methotrexate (MTX) in a sample. The methods disclosed herein decrease cross-reactivity and improve sensitivity of the detection.